Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 7, 2024
Deals
Tizona searching for new partner after Gilead declines buyout option
Gilead retains ownership of nearly half of Tizona’s equity via $300M investment in 2020, but won’t take full control of anti-HLA-G antibody
BioCentury | Nov 19, 2021
Deals
Momentum for TIGIT, adenosine with Gilead’s grab of Arcus options
While disclosed data remain limited, Gilead highlights potential for combos
BioCentury | Oct 21, 2021
Emerging Company Profile
Elpiscience builds out global pipeline with CD39 focus
Dual-track strategy includes in-licensing for China market, but focus is on driving wholly-owned pipeline in U.S.
BioCentury | May 20, 2021
Product Development
Adenosine pathway inhibitors at ASCO21: Data Byte
Adenosine pathway inhibitors from I-Mab and Arcus showed higher response rates than competitors at ASCO21. Extracellular adenosine dampens antitumor immunity by interacting with adenosine receptors on
BioCentury | Dec 12, 2020
Translation in Brief
Fecal transplant improves checkpoint inhibitor response in Phase I; plus Secarna’s antitumor antisense oligos, a blood-based mRNA test for Alzheimer’s and more
BioCentury’s roundup of translational news
BioCentury | May 21, 2020
Product Development
May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more
BioCentury | May 24, 2019
Preclinical News
May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen
BioCentury | Mar 7, 2019
Translation in Brief
Blocking B cell vesicles to enhance chemotherapy
Inhibiting extracellular vesicles formation could enhance chemotherapy’s efficacy
BioCentury | Jan 11, 2019
Finance
Exscientia looks inward
How Exscientia plans to use $26M B round to build out AI-driven pipeline
Items per page:
1 - 10 of 24